---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-22-000945"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2022-07-28T23:59:59+00:00"
generated_at: "2026-06-24T07:18:54.364274+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alnylam Q2 product revenue $214M (+33%); AMVUTTRA FDA approved; guidance reiterated

## Summary
- Q2 net product revenues $214M: ONPATTRO $153M, GIVLAARI $45M, OXLUMO $15M, up 33% YoY.
- FDA approved AMVUTTRA (vutrisiran) for hATTR polyneuropathy; 133 start forms in first weeks.
- GAAP net loss $277M ($2.29/share) vs $190M loss year ago; non-GAAP loss $246M ($2.03).
- Reiterated FY2022 guidance: combined product revenue $870-$930M, R&D+SG&A $1.62-$1.70B.
- Expects APOLLO-B topline results within 3 weeks; cash $2.11B.

## SEC filing metadata
- accession: 0001157523-22-000945
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2022-07-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000115752322000945/0001157523-22-000945-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000115752322000945/a52793912.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-22-000945
- JSON: https://secwatch.observer/filing/0001157523-22-000945.json
- Plain text: https://secwatch.observer/filing/0001157523-22-000945.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.